The historical rank and industry rank for Caplin Point Laboratories's Days Payable or its related term are showing as below:
NSE:CAPLIPOINT'
s Days Payable Range Over the Past 10 Years
Min: 61.99 Med: 100.76 Max: 147.17
Current: 101.58
During the past 13 years, Caplin Point Laboratories's highest Days Payable was 147.17. The lowest was 61.99. And the median was 100.76.
NSE:CAPLIPOINT's Days Payable is ranked better than 55.64% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NSE:CAPLIPOINT: 101.58
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CAPLIPOINT vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caplin Point Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Caplin Point Laboratories's Days Payable falls into.
Caplin Point Laboratories Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Caplin Point Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Days Payable of 110.26 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Caplin Point Laboratories and its competitors. This is near median its historical median of 100.76. Over the past decade, Caplin Point Laboratories' Days Payable has ranged from 61.99 to 147.17. According to the industry distribution chart, Caplin Point Laboratories ranks #409 out of 922 companies in the Drug Manufacturers industry, placing it in the top 44.4%.
Is Caplin Point Laboratories' Days Payable too high?
Caplin Point Laboratories' current Days Payable of 110.26 is near median its 10-year median of 100.76. Over the past 10 years, this metric has ranged from a low of 61.99 to a high of 147.17. The Drug Manufacturers industry median Days Payable is 90.84. Caplin Point Laboratories' value of 110.26 is 21.4% above this industry median. Based on the distribution chart, Caplin Point Laboratories ranks #409 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Caplin Point Laboratories has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #409 out of 922 companies for Days Payable. This puts Caplin Point Laboratories in the upper half of its industry. The industry median Days Payable is 90.84. Caplin Point Laboratories' value of 110.26 is 21.4% above this benchmark. Historically, Caplin Point Laboratories' own Days Payable has ranged from 61.99 to 147.17 over the past decade. While the company's 10-year median is 100.76 vs. the industry median of 90.84, Caplin Point Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caplin Point Laboratories's current Days Payable of 110.26 is 21.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Caplin Point Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current Days Payable is 110.26, which is near median its own 10-year median of 100.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,078.80, compared to a current price of ₹2,538.20 — trading 22.1% above its estimated fair value. The current Days Payable is 110.26, which is near median its 10-year median of 100.76 and 21.4% above the Drug Manufacturers industry median of 90.84. Caplin Point Laboratories' overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Days Payable is 110.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued.
The current stock price of ₹2,538.20 is trading 22.1% above its estimated GF Value™ of ₹2,078.80.
GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:CAPLIPOINT:
Days Payable: 110.26 (near median its 10-year median of 100.76)
GF Value™: ₹2,078.80 vs. price of ₹2,538.20 (22.1% above fair value)
Industry Position: 21.4% above the Drug Manufacturers median (#409 of 922)
No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
92GF Score
Get the complete analysis for NSE:CAPLIPOINT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAPLIPOINT has been successfully added to your 
